Cytonics Announces Issuance of US Patent for the APIC-PRP System and a Method of Producing Recombinant Alpha-2-Macroglobulin (A2M) Variants

NOVEMBER 22, 2016
Jupiter, FL:
Cytonics Corporation, a biotechnology company focused on the development of biologic therapies for musculoskeletal diseases, today announced that the United States Patent Office issued patent US 9,498,514 covering both a biological composition of concentrated Alpha-2-Macroglobulin (A2M) and a recombinant variant of the naturally occurring A2M molecule. This proprietary technology is being developed to treat cartilage degeneration in diseases such as osteoarthritis.

Alpha-2-Macroglobulin (A2M) is an abundant, endogenous blood protein that inhibits all classes of serine proteases and metalloproteases, thereby decreasing protein degradation involved in osteoarthritis and attenuating joint pain. Cytonics’ recombinant Alpha-2-Macroglobulin variant, Cyt-108, is a synthesized protein that contains a series of mutations within the bait region of the protein structure. The mutated bait region was designed to increase the potency of the A2M molecule, allowing small doses to have large therapeutic effects.

“We are confident that Cytonics’ innovative recombinant A2M variant, Cyt-108, will translate into clinical success. Our autologous A2M therapy has already demonstrated outstanding success in practice, which gives us a tremendous amount of confidence that Cyt-108 will be an effective treatment for osteoarthritis.”

Gaetano Scuderi, MD
Founder and CEO of Cytonics

About Cytonics:

Cytonics, founded in 2006, is a private research and development company focusing on molecular diagnostic and therapeutic products for chronic musculoskeletal diseases. The company developed the FACT diagnostic test which helps identify the source of back and joint pain and assists physicians in determining the most appropriate treatment. Cleared in January of 2014, Cytonics developed the Autologous Platelet-Integrated Concentrate (APIC) System as a platelet-rich-plasma (PRP) device. In addition, the company also developed autologous cell-free A2M
concentrate and other forms of A2M therapeutics, including optimized recombinant forms. The company is currently pursuing pre-clinical studies for their lead recombinant A2M candidate, Cyt-108.

658 W. Indiantown Rd. Suite 214
Jupiter, FL 33458